We’re delighted to announce a new collaboration between HEMEX and The Bioinformatics CRO which will provide an even more complete CRO service for our start-ups! Find out how this collaboration can support you throughout your Clinical Development phase.
Benz Advisory, mediacrewgroup, and HEMEX join forces to support early-stage companies with strategic communications through a new service called Comms&Media. Targeted at early-stage businesses from all industries, it offers a unique, holistic approach to help companies develop and implement effective external and internal communications.
Resistell has started the Performance Evaluation Study (PES) of its groundbreaking nanomotion technology at Lausanne University Hospital. At HEMEX, are very happy to be part of this project, as we will be monitoring the clinical trial over the next 12 months.
We’re thrilled to announce an exciting new partnership between HEMEX and YouEngineering, a software engineering company which aims to foster digital progress. Our latest partnership enables us to provide healthcare start-ups with a new range of digital packages to guarantee our clients the best results in mobile app, software development, and web design.
HEMEX is delighted to announce an exciting new partnership with Avanti Europe. The
Avanti Europe team is a specialist consultancy and expert knowledge provider. This
partnership will allow us to complete the range of products we provide to healthcare start-ups to ensure we continue offering excellent support within the life science industry.
BLKB, Hemex and Launchpad aim to support young entrepreneurs in their business activities through the start-up incubator program, inQbator. The program is open to start-ups from all industries. The main aim of inQbator is to promote innovation in the region.
HEMEX is delighted to announce our exciting new partnership with SMART-TRIAL. Collecting and managing clinical data has been revolutionized for the MedTech industry and we are pleased that eCRF, eConsent, and more can now be done with confidence. This partnership enables us to provide healthcare start-ups with a complete range of packages to ensure conducting clinical trials, PMCF studies, and monitoring is made easy and affordable.
Our portfolio company Opterion Health AG announced today the successful agreement of a EUR 8.4m Bridge Financing
Round. The proceeds from this financing round will be used to complete preclinical activities and prepare for entry into Phase I. Heartfelt congratulations on your success, Opterion!
Our portfolio company ASPIVIX SA announced last week the completion of and interim analysis results from its Phase I first-in-women trial. The two-phase ADVANCE Women trial is assessing the usability, efficacy, and safety of the investigational CAREVIX, the innovative device designed as a modern and gentler alternative. Warmest congratulations on your achievement, ASPIVIX!